Your browser doesn't support javascript.
loading
Tau protein phosphorylation as a therapeutic target in Alzheimer's disease.
Lau, Lit-Fui; Schachter, Joel B; Seymour, Patricia A; Sanner, Mark A.
Afiliação
  • Lau LF; CNS Discovery, Pfizer Global Research and Development, Groton, CT 06340, USA. lit-fui_lau@groton.pfizer.com
Curr Top Med Chem ; 2(4): 395-415, 2002 Apr.
Article em En | MEDLINE | ID: mdl-11966463
Neurofibrillary tangles (NFTs) are a distinguishing neuropathological feature found in postmortem brains of Alzheimer s disease (AD) and tauopathy patients. The density of these lesions correlates with severity of AD and their distribution follows a characteristic pattern of expansion as the disease progresses. The principle components of NFTs are highly phosphorylated forms of the microtubule-associated protein, tau. Tau phosphorylation is believed to initiate or facilitate dissociation from microtubules leading to microtubule destabilization, decay of cellular transport properties, and cell death. This review summarizes recent data and prevailing views on the roles of protein kinases and phosphatases in the regulation of tau phosphorylation in vitro and in vivo, taking into account data from human neurodegenerative diseases and from transgenic rodent models. Small molecule inhibitors of tau phosphorylation that serve as important research tools and possibly the basis of potential new therapeutics, are also described. Key challenges in developing effective therapeutic agents include identification of the relevant kinase(s) responsible for aberrant tau phosphorylation in AD, synthesis of inhibitors selectively targeting those kinases and establishment of appropriate animal models.
Assuntos
Buscar no Google
Base de dados: MEDLINE Assunto principal: Proteínas tau / Doença de Alzheimer Idioma: En Ano de publicação: 2002 Tipo de documento: Article
Buscar no Google
Base de dados: MEDLINE Assunto principal: Proteínas tau / Doença de Alzheimer Idioma: En Ano de publicação: 2002 Tipo de documento: Article